πŸ‡ΊπŸ‡Έ FDA
Patent

US 12415856

EGFR x CD28 multispecific antibodies

granted A61KA61K2039/505A61K2039/507

Quick answer

US patent 12415856 (EGFR x CD28 multispecific antibodies) held by REGENERON PHARMACEUTICALS, INC. expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Sep 16 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
10
CPC classes
A61K, A61K2039/505, A61K2039/507, A61K2039/572, A61K39/3955